Clinical Trial

The Eplontersen Pregnancy and Lactation Outcomes Study

Study acronym: EPPRO
Recruiting
View on ClinicalTrials.gov →
Summary
The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant associated with exposure to eplontersen during pregnancy and/or lactation.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-10-02; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT07205666
Lead Sponsor AstraZeneca
Collaborators: ICON plc
Conditions Transthyretin Amyloidosis
Enrollment 10 participants
Start Date 2025-11-30
Primary Completion 2035-12-30 (estimated)
Study Completion 2035-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22